Repercussões adversas do uso de agonistas do GLP-1: uma revisão narrativa de literatura
DOI:
https://doi.org/10.34119/bjhrv8n5-040Keywords:
peptídeo 1 semelhante ao glucagon, efeitos adversos, redução de pesoAbstract
O objetivo do presente estudo foi investigar as principais repercussões adversas dos agonistas dos receptores para o peptídeo 1 semelhante ao glucagon (GLP-1). Esta revisão narrativa de literatura foi elaborada de acordo com as recomendações da Preferred Items for Systematic Reviews and Meta-Analysis Statement (PRISMA). A estratégia de busca [ (GLP[Title]) AND (side[Title] OR adverse[Title] OR complication[Title]) ] foi utilizada para identificar artigos na base de dados PubMed. Foram incluídos apenas estudos publicados a partir do ano de 2015, em português ou inglês, com disponibilidade do texto completo gratuito. Os artigos foram triados conforme os critérios de elegibilidade pré-determinados. Apesar dos avanços científicos, efeitos adversos como náuseas, vômitos e constipação são frequentes e podem levar à descontinuação do tratamento. Dados revelam relatos de tontura, tremores, disgeusia e alterações do humor, como ansiedade, depressão e ideação suicida, especialmente com o uso de Liraglutida e Semaglutida. A maioria dos efeitos adversos surge no primeiro mês de uso e, embora raros, requerem vigilância clínica. Outro aspecto relevante diz respeito aos eventos otorrinolaringológicos, como disgeusia, sinusite, faringite e zumbido, com maior frequência relatada em usuários de Semaglutida. O uso expandido dessas medicações, inclusive por indivíduos sem indicação formal, reforça a importância do monitoramento contínuo e da realização de estudos longitudinais para melhor compreensão do perfil de segurança a longo prazo.
References
ALZAID, Aus et al. Burden of disease and costs associated with type 2 diabetes in emerging and established markets: systematic review analyses. Expert Review of Pharmacoeconomics & Outcomes Research, p. 1-14, 20 jul. 2020.
BETHEL, M. Angelyn et al. HbA1c change and diabetic retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: a meta-analysis and meta-regression. Diabetes Care, v. 44, n. 1, p. 290-296, 21 dez. 2020.
CHEN, He et al. Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System. Scientific Reports, v. 15, n. 1, 24 maio 2025.
CHEN, Wei et al. Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database. Frontiers in Endocrinology, v. 15, 6 fev. 2024.
CHUONG, Vicky et al. The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight, 16 maio 2023.
DOUROS, Jonathan D.; FLAK, Jonathan N.; KNERR, Patrick J. The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP. Frontiers in Endocrinology, v. 16, 3 fev. 2025.
DRUCKER, Daniel J. GLP-1 physiology informs the pharmacotherapy of obesity. Molecular Metabolism, v. 57, p. 101351, mar. 2022.
GBD 2021 ADULT BMI COLLABORATORS. Global, regional, and national prevalence of adult overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. The Lancet, v. 405, n. 10481, p. 813-838, mar. 2025.
GRECO, Eulalia et al. GLP-1 receptor agonists and kidney protection. Medicina, v. 55, n. 6, p. 233, 31 maio 2019.
JENSEN, Lene et al. Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. European Journal of Pharmaceutical Sciences, v. 104, p. 31-41, jun. 2017.
KHAN, Faizaan I. et al. Otolaryngologic side effects of GLP‐1 receptor agonists. The Laryngoscope, 12 fev. 2025.
KOPP, Katherine O. et al. Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: implications for neurodegenerative disease treatment. Pharmacological Research, p. 106550, nov. 2022.
LI, Qiu-Xuan et al. GLP-1 and underlying beneficial actions in Alzheimer’s disease, hypertension, and NASH. Frontiers in Endocrinology, v. 12, 6 set. 2021.
LIU, Lulu et al. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database. Frontiers in Endocrinology, v. 13, 7 dez. 2022.
LIU, Qiyuan Keith. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Frontiers in Endocrinology, v. 15, 24 jul. 2024.
LU, Jinmiao et al. A potentially serious adverse effect of GLP-1 receptor agonists. Acta Pharmaceutica Sinica B, mar. 2023.
MA, Xiaoxuan et al. GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential. International Journal of Biological Sciences, v. 17, n. 8, p. 2050-2068, 2021.
MCLEAN, Brent A. et al. Revisiting the complexity of GLP-1 action-from sites of synthesis to receptor activation. Endocrine Reviews, 15 dez. 2020.
MIN, Jee Sun et al. A comprehensive review on the pharmacokinetics and drug−drug interactions of approved GLP-1 receptor agonists and a dual GLP-1/GIP receptor agonist. Drug Design, Development and Therapy, Volume 19, p. 3509-3537, abr. 2025.
MÜLLER, T. D. et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, v. 30, p. 72-130, dez. 2019.
MUNIR, Mubbasher et al. Global human obesity and global social index: relationship and clustering. Frontiers in Nutrition, v. 10, 9 mar. 2023.
NANAYAKKARA, Natalie et al. Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses. Diabetologia, 14 dez. 2020.
PAGE, Matthew J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Journal of Clinical Epidemiology, v. 134, p. 178-189, jun. 2021.
PAN, Heng-Chih et al. GLP-1 receptor agonists’ impact on cardio-renal outcomes and mortality in T2D with acute kidney disease. Nature Communications, v. 15, n. 1, 13 jul. 2024.
RAZA, Fatima Ali et al. Effect of GLP-1 receptor agonists on weight and cardiovascular outcomes: a review. Medicine, v. 103, n. 44, p. e40364, 1 nov. 2024.
SHEAHAN, Kelsey H.; WAHLBERG, Elizabeth A.; GILBERT, Matthew P. An overview of GLP-1 agonists and recent cardiovascular outcomes trials. Postgraduate Medical Journal, v. 96, n. 1133, p. 156-161, 4 dez. 2019.
SMITH, Nicholas K. et al. GLP-1: molecular mechanisms and outcomes of a complex signaling system. Neurochemistry International, v. 128, p. 94-105, set. 2019.
STRELITZ, Jean et al. Association between weight change and incidence of cardiovascular disease events and mortality among adults with type 2 diabetes: a systematic review of observational studies and behavioural intervention trials. Diabetologia, v. 65, n. 3, p. 424-439, 2 dez. 2021.
THOMSEN, Reimar W. et al. Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP‐1RA‐based weight‐loss therapies. Diabetes, Obesity and Metabolism, 8 abr. 2025.
TOBAIQY, Mansour; ELKOUT, Hajer. Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database. International Journal of Clinical Pharmacy, 24 jan. 2024.
WANG, Bin et al. Assessing the impact of type 2 diabetes on mortality and life expectancy according to the number of risk factor targets achieved: an observational study. BMC Medicine, v. 22, n. 1, 13 mar. 2024.
ZHAO, Xin et al. GLP-1 receptor agonists: beyond their pancreatic effects. Frontiers in Endocrinology, v. 12, 23 ago. 2021.
